InvestorsHub Logo
Followers 220
Posts 1626
Boards Moderated 0
Alias Born 01/05/2005

Re: highflier post# 31803

Sunday, 04/08/2012 4:53:23 PM

Sunday, April 08, 2012 4:53:23 PM

Post# of 75926
WOW YOU ARE NOT GOING TO BELIEVE THIS...

I guess PSG must be reading what I have been posting for the past month. Look at the wording they are now using in their latest update on SNDY. They are now saying the INSIDERS know what is going on within the company and one of the reasons is the fact they retired 150 million shares.

If you have not already done so please read my sticky posted above on 3/30. It will certainly give you my thoughts on sndy and what the insiders are doing. Like I have been saying always, always follow the insiders, especially when they are making moves like they have done in the past few months. Enjoy the read

Mike

Penny Stock Geeks SNDY DD Update- Sun, April 8th, 2012

Good afternoon members,

Since our initial alert on SNDY (Solos Endoscopy) to VIP members back in January at .0008 cents the stock has outperformed all expectations when it surged over 2,000% to hit a high of .243 cents in just under 3 months. This is an example of why we all trade Penny Stocks and the opportunity that lies therein. This is also an indication of what we strive for here at Penny Stock Geeks to bring the best possible picks and alerts for our team. SNDY has seen a recent retrace with the stock currently sitting at .0115 cents. It has been a slow week with lower than average volume due to the holidays and we expect to see a bounce and run in the coming days. With the latest Paragon Financial Analysts report on SNDY comparing it next to OPK Health which is on the NYSE exchange and trading just below $5 dollars per share, we believe something big is happening behind the scenes.

There is major buzz surrounding the investment community including possible buyout/ takeover talks which could be a potential reality considering the company has developed state of the art Medical Cancer detecting technology which is in high demand and one which could be a big gain and an added benefit for bigger players such as OPK Health. As a result we have labelled SNDY as the next " LIFE CHANGER" medical OTC Penny Stock of the year. We believe the stock could possibly see anywhere from .50 cents to $1 dollar in the next 6 to 12 months. We are expecting some big news this year and from the due diligence we have done on this medical cancer related stock, we believe SNDY will beat all expectations for this year.

Solos Endoscopy has struggled over the years and appears to have grained some major ground in turning the company around after their hard work and dedication. This is a medical company which has been in business since 1986. In a multi billion dollar worldwide Cancer business, SNDY has the opportunity to get to the next level and become extremely profitable while helping save lives of women across the world in their fight with Breast Cancer. Breast Cancer is on the rise among the worlds billions of women and is increasing at an alarming rate. The critical need for early detection, diagnosis and treatment has become overwhelming. SNDY has the technology, technical expertise and experience to help fix this problem.

With the CE Mark approval for the newly designed MammoView Breast Cancer system and the Mammoview SteriTap, we believe SNDY is ready to open the doors and grab 1% of the total market of the multi billion dollar Cancer industry. With its most recent news of reducing their net loss by over $688,000 dollars, 150 Million share reduction by "INSIDERS", pending new Mammoview Breast Cancer detection system, CE Mark, Mammoview device attachments and expectation to be debt free by the 2nd quarter of 2012, we believe we are sitting in the drivers seat which will lead many investors to new found wealth in the coming months ahead from here. The biggest giveaway is the "INSIDERS" own 150 million share reduction which proves to us that the company is ever so confident to invest their own money on the line knowing the outcome will be tremendous for them and investors within the next 6 to 12 months.